Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders primarily in the United States. Its product development pipeline includes NNZ-2566 that is in Phase II clinical trials in rett syndrome, fragile X syndrome, and moderate to severe traumatic brain injury, as well as in concussion; and NNZ-2591, which is in preclinical development for chronic neurodegenerative conditions. The company has collaborative relationship with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.
neuren pharmaceuticals ltd
(NEU:Australian Stock Exchange Ltd)
697 Burke Road
Camberwell, VIC 3124
Phone: 61 3 9092 0480
|No competitor information is available for NEU.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact NEUREN PHARMACEUTICALS LTD, please visit www.neurenpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.